US 12,469,588 B2
Distributions comparison in pretreatment patient-QA
Pasquale Tamborra, Terlizzi (IT)
Assigned to ISTITUTO TUMORI “GIOVANNI PAOLO II” I.R.C.C.S., Bari (IT); and Pasquale Tamborra, Terlizzi (IT)
Appl. No. 17/440,676
Filed by ISTITUTO TUMORI “GIOVANNI PAOLO II” I.R.C.C.S., Bari (IT); and Pasquale Tamborra, Terlizzi (IT)
PCT Filed Sep. 24, 2019, PCT No. PCT/IT2019/000076
§ 371(c)(1), (2) Date Sep. 17, 2021,
PCT Pub. No. WO2021/105930, PCT Pub. Date Apr. 1, 2021.
Prior Publication US 2022/0068459 A1, Mar. 3, 2022
Int. Cl. G16H 20/40 (2018.01); A61N 5/10 (2006.01); G16H 40/60 (2018.01)
CPC G16H 20/40 (2018.01) [A61N 5/1031 (2013.01); A61N 5/1071 (2013.01); G16H 40/60 (2018.01)] 20 Claims
OG exemplary drawing
 
1. A method for verifying a calculated radiation dose distribution produced by TPS (treatment planning system) software, in a patient treatment plan of radiotherapy, before delivery of the radiation dose to a patient, in order to avoid clinically relevant dose differences in tumors and organs at risk, the method comprising the steps of:
converting operator selected isodose levels into volumetric 3D structures termed isodose structures; and
using the isodose structures to verify operator selected CRDVCs (Clinical Relevant Dose Volumetric Conditions) and their relative spatial correspondence thus detecting all the dose differences in organs at risk (OARs) and in PTV (Planning Target Volume) responsible for inadequacy of gamma analysis for the clinical assessment of a TPS plan, and
delivering the patient treatment plan of radiotherapy to the patient.